Efficacy of Vitamin D in Colorectal Cancer Chemoprevention
Colorectal Cancer
About this trial
This is an interventional prevention trial for Colorectal Cancer focused on measuring Assess the efficacy of vitamin D for preventing colorectal cancer and identifying the populations likely (or unlikely) to benefit from vitamin D-based therapy., Evaluate the ability of Vitamin D3 (cholecalciferol) to reduce ACF's in humans.
Eligibility Criteria
Inclusion Criteria:
- All non-pregnant patients 50 years of age or older with 10 or more ACFs.
Exclusion Criteria:
- The following will be specifically looked for, and result in patients not being eligible for study enrollment:
- Use of non-steroidal anti-inflammatory drugs or glucocorticosteroids within 60 days of study entry.
- History of chronic IBD or prior pelvic radiation (inflammation distorts crypt pattern).
- Intake of any vitamin D or calcium supplements within 60 days of study entry.
- Patients with increased bleeding risk from biopsy protocol (i.e. renal failure, decompensated cirrhosis, blood dyscrasia
Sites / Locations
- University of Illinois at Chicago Medical Center
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Vitamin D3 (cholecalciferol)
Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.